Antithrombin supplementation and risk of bleeding in patients with sepsis-associated disseminated intravascular coagulation
详细信息 查看全文
- 作者：Toshiaki Iba ; M.D.a ; toshiiba@cf6.so-net.ne.jp" class="auth_mail" title="E-mail the corresponding author ; Satoshi Gando ; M.D.b ; gando@med.hokudai.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Daizoh Saitoh ; M.D.c ; ds0711@ndmc.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Hideo Wada ; M.D.d ; wadahide@clin.medic.mie-u.ac.jp" class="auth_mail" title="E-mail the corresponding author ; Marcello Di Nisio ; M.D.e ; mdinisio@unich.it" class="auth_mail" title="E-mail the corresponding author ; Jecko Thachil ; M.D.f ; Jecko.thachil@cmft.nhs.uk" class="auth_mail" title="E-mail the corresponding author
- 关键词：Antithrombin ; Bleeding ; Disseminated intravascular coagulation ; Sepsis ; Thrombomodulin
- 刊名：Thrombosis Research
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：145
- 期：Complete
- 页码：46-50
- 全文大小：320 K
文摘
- class="listitem" id="list_l0005">
- class="label">•
Bleeding event was recognized in 5.36% (major 1.75%) with antithrombin substitution.
- class="label">•
Sustained DIC is the strongest risk factor of bleeding in sepsis-associated DIC.
- class="label">•
Bleeding was not increased by higher dose (3000 IU/day) of antithrombin.
- class="label">•
Bleeding was not increased by the co-administration of recombinant thrombomodulin.